FONDATION-IPSEN
23.5.2017 07:32:05 CEST | Business Wire | Press release
The Fondation IPSEN (1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. The Fondation IPSEN Endocrine Regulations Prize (2) will be presented today at the ECE (European Congress of Endocrinology) in Lisbon. An international jury (3) chaired by Professor Iain Robinson (National Institute for Medical Research, London, UK ), awarded the prize to Bruce Mc Ewen for his pioneering work on glucocorticoids, stress and neuronal degeneration.
The Fondation IPSEN(1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians from different backgrounds. Created in 2002, the Endocrine Regulations Prize(2) of the Fondation IPSEN awards renowned specialists who made breakthrough discoveries or significant progress in the field. Pr Bruce McEwen has been awarded by an international jury(3) for his pioneering work on glucocorticoids, stress and neuronal degeneration. The prize will be presented at the ECE (European Congress of Endocrinology), followed by a lecture given by Bruce McEwen.
During his talk, Bruce McEwen will discuss about the role of the steroid
hormones that are produced in the brain which mediate every aspect of
brain function. This has broadened the definition of
‘neuroendocrinology’ to include the reciprocal communication between the
brain and the body via hormonal and neural pathways.
The brain is
the central organ of stress and adaptation to stress because it
perceives and determines what is threatening, as well as the behavioural
and physiological responses to the stressor. The adult and developing
brain possess remarkable structural and functional plasticity in
response to stress, including neuronal replacement, dendritic
remodelling, and synapse turnover. Stress causes an imbalance of neural
circuitry subserving cognition, decision-making, anxiety and mood. This
imbalance, in turn, affects systemic physiology via neuroendocrine,
autonomic, immune and metabolic mediators. In the short term, as for
increased fearful vigilance and anxiety in a threatening environment,
these changes may be adaptive. But, if the danger passes and the
behavioural state persists along with the changes in neural circuitry,
such maladaptation may need intervention with a combination of
pharmacological and behavioural therapies, as is the case for chronic
anxiety and depression. Moreover, adverse early-life experience, produce
lasting effects on brain and body over the life-course via epigenetic
mechanisms. While prevention is most important, the plasticity of the
brain gives hope for therapies that take into consideration brain–body
interactions.
Biography
Bruce S. McEwen obtained his Ph.D. in Cell
Biology in 1964 from The Rockefeller University.
He is a member
of the US National Academy of Sciences, the National Academy of
Medicine, and the American Academy of Arts and Sciences. He served as
President of the Society for Neuroscience in 1997-98. As a
neuroscientist and neuroendocrinologist, McEwen studies
environmentally-regulated, variable gene expression in brain, mediated
by circulating steroid hormones and endogenous neurotransmitters in
relation to brain sexual differentiation and the actions of sex and
stress hormones on the adult brain. His laboratory discovered adrenal
steroid receptors in the hippocampus in 1968 that was the gateway for
discovering effects of circulating hormones on cognitive function, mood
regulation and other CNS functions. His laboratory combines molecular,
anatomical, pharmacological, physiological and behavioral methodologies
and relates their findings to human clinical information. His current
research focuses on stress effects on amygdala and prefrontal cortex, as
well as hippocampus, and his laboratory also investigates sex hormone
effects and sex differences in these brain regions involved in cognitive
function and mood regulation. He served on the MacArthur Foundation
Research Network on Socioeconomic Status and Health, in which he has
helped to reformulate concepts and measurements related to stress and
stress hormones in the context of human societies. This led to the
concept of “allostatic load and overload” that describes the wear and
tear on the body and brain from chronic stress and related life style
behaviors that lead to dysregulation of physiological stress pathways
that are normally protective.
He is also a member of the National
Council on the Developing Child which focuses on biological embedding of
early life experiences and promoting healthy brain development.
He
is the co-author of a book with science writer, Elizabeth Lasley, for a
lay audience called “The End of Stress as We Know It”, published in
2002, and “The Hostage Brain” with science writer, the late Harold M.
Schmeck, Jr., published in 1994.
(1) The Fondation IPSEN
Established in 1983 under the
aegis of the Fondation de France, the ambition of the Fondation IPSEN is
to initiate a reflection about the major scientific issues of the
forthcoming years. The long-standing mission of the Fondation IPSEN is
to contribute to the development and dissemination of scientific
knowledge by fostering interaction between scientists and clinicians. It
has developed an important international network of scientific experts
who meet regularly at meetings known as Colloques Médecine et
Recherche
, dedicated to three main topics: neurosciences,
endocrinology and cancer science. Moreover the Fondation IPSEN has
started several series of meetings in partnership with the Salk
Institute, the Karolinska Institute as well as with the journals Cell
and Science
. The Fondation IPSEN produced several hundred
publications and more than 250 scientists have been awarded prizes and
grants.
www.fondation-ipsen.org
(2) The Endocrine Regulations Prize laureates
Created
in 2002, this Prize of
the Fondation Ipsen
has been
awarded to following the renowned specialists: Wylie VALE
(2002), Robert
LEFKOWITZ
(2003), Pierre CHAMBON
(2004), Thomas HÖKFELT
(2005), Roger CONE
(2006), William CROWLEY
(2007), Ronald
EVANS
(2008), Gilbert VASSART
(2009), Shlomo MELMED
(2010), Paolo SASSONE-CORSI
(2011), Jeffrey M. FRIEDMAN
(2012), Bert O’MALLEY
(2013), Maria I. NEW
(2014), C.
Ronald Kahn
(2015) and John W. FUNDER
(2016).
(3) Members of the jury
Iain ROBINSON
(National
Institute for Medical Research, London, UK)
, President
Xavier
BERTAGNA
(Hôpital Cochin, Paris, France)
Felipe
CASANUEVA
(University of Santiago de Compostela, Santiago de
Compostela, Spain)
Michael CONN
(Texas Tech
University Health Sciences Center, El Paso, USA)
Ezio GHIGO
(Ospedale Molinette, Turin, Italy)
Ilpo HUHTANIEMI
(Imperial
College Faculty of Medicine, London, UK)
Gérard KARSENTY
(Columbia
University Medical Center, New York, USA)
Paul KELLY
(Faculté
de Médecine Necker Enfants Malades, Paris, France)
Stafford
LIGHTMAN
(University of Bristol, Bristol, UK)
Günter
STALLA
(Max Planck Institute of Psychiatry, München, Germany
Phyllis
WISE
(University of Illinois, Urbana, USA).
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005878/en/
Contact:
Fondation IPSEN
Yannick TANGUY, Tel. : +33 (0)1 58 33 50 00
E-mail
: fondation@ipsen.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Value Group Brings Its Integrated Global IROPS Management Model to the World Aviation Festival8.10.2026 08:32:00 CEST | Press release
Value Group, a leading provider of integrated aviation disruption management solutions, returns to the World Aviation Festival as a Gold Sponsor, reinforcing its role in the evolution of airline disruption management. From 13 to 15 October at FIL in Lisbon, the event is one of the aviation industry’s leading international technology conferences and exhibitions, bringing together airlines, airports and travel technology companies worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007885823/en/ Thomas Sergnese, Co-CEO & Chief Commercial Officer and Daniele Bocchieri, Co-CEO & Chief Operating Officer At stand 1-180, Value Group will showcase the evolution of its integrated disruption management model and the RUBIK digital ecosystem, demonstrating how technology, operations and governance can work together as one connected system to manage irregular operations more effectively at both global and local level. Over the p
Colruyt Group Crosses the 150 Store Milestone With Rollout of Toshiba ELERA® Self Service Store Deployments8.10.2026 07:30:00 CEST | Press release
Toshiba’s ELERA® Self Service successfully deployed across Okay, Okay City, Spar Colruyt Group and Bio-Planet stores in Belgium Toshiba Global Commerce Solutions today announced the successful deployment of its ELERA® Self Service solution across 144 Colruyt Group stores: Okay, Okay City, Spar Colruyt Group and Bio-Planet. Today, 454 self-checkout systems have already been installed year-to-date across 150 stores. The project continues to expand, with an additional 51 stores planned in 2026 and further rollout in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007465701/en/ Toshiba’s ELERA® Self Service successfully deployed across Okay, Okay City, Spar Colruyt Group and Bio-Planet stores in Belgium. The deployment was designed to support a fast, intuitive, and customer-friendly checkout experience, while maintaining the personal interaction that remains important within the convenience retail environment. Across the
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older8.10.2026 07:00:00 CEST | Press release
New Nemluvio® (nemolizumab) post-hoc data from the ARCADIA long-term extension (LTE) study showed the majority of Week 16 responders maintained deep and lasting skin lesion and itch response for up to three years1 Additional long-term data further demonstrate Nemluvio’s consistent safety profile and sustained efficacy, including improvements in skin clearance, itch, sleep and quality of life in adults with prurigo nodularis up to 148 weeks, and people with atopic dermatitis aged 12 and older up to 152 weeks2,3 Phase II pediatric data will also be presented, with nemolizumab driving meaningful and sustained improvements in children aged 2-11 years with moderate-to-severe atopic dermatitis4 Alongside a product theatre exploring how targeted IL-31 treatment may impact patient outcomes, these findings reinforce Galderma's leadership in advancing treatment goals in atopic dermatitis and prurigo nodularis Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new da
Fuji Electric Joins Helical Fusion as Strategic Investor and Official Partner as Series B Second Close Raises JPY 3.23 Billion8.10.2026 02:00:00 CEST | Press release
Major Japanese industrial players join Helical Fusion as construction of Helix HARUKA advances through a public-private partnership spanning government, national research infrastructure, and Japan’s manufacturing sector Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator with the goal of achieving commercially viable fusion power in the 2030s, today announced the completion of a JPY 3.23 billion (approximately USD 20.6 million) Series B second close. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007813917/en/ Helical Fusion and new investors for the Series B 2nd close The round marks another expansion of the industrial coalition forming around Helical Fusion’s Helix Program. Fuji Electric Co., Ltd., one of Japan’s major electrical and industrial equipment manufacturers, has joined Helical Fusion as both an investor and an Official Partner of the Helix Program. Other new investors in the sec
New INRIX Parking Scorecard Reveals Cities with the Most Parking, Highest Prices, and Lowest Availability7.10.2026 22:16:00 CEST | Press release
The Scorecard analyzes more than 120 downtown areas across North America and Europe, comparing parking availability, prices and curb use policies INRIX, a leader in transportation analytics and mobility intelligence, today released its first-ever INRIX Parking Scorecard, the largest comparative analyses of downtown parking conditions across North America and Europe. Drawing on parking availability, curb regulations, pricing data and parking infrastructure from more than 120 downtown areas in 14 countries, the report reveals significant differences in parking conditions and how cities allocate curb space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007322796/en/ New INRIX Parking Scorecard: Where Downtown Parking Costs Most The Scorecard examines parking availability: the probability of finding a parking space alongside on-street and off-street parking pricing, and curb use policies. The findings show that parking condi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
